
Annual report 2024
added 03-31-2025
NeuroMetrix Net Debt 2011-2026 | NURO
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt NeuroMetrix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.49 M | -3.98 M | -22 M | -4.63 M | -1.62 M | -6.78 M | -4.04 M | -3.95 M | -12.5 M | -9.22 M | -9.2 M | -8.68 M | -10.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -1.49 M | -22 M | -7.56 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M | ||
|
Baxter International
BAX
|
11.5 B | $ 20.66 | 1.27 % | $ 10.5 B | ||
|
Becton, Dickinson and Company
BDX
|
17.1 B | $ 205.09 | 1.16 % | $ 59 B | ||
|
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | ||
|
Ekso Bionics Holdings
EKSO
|
-5.61 M | $ 8.15 | -7.6 % | $ 164 M | ||
|
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
2.46 B | $ 80.67 | -0.38 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
-59.2 M | $ 42.59 | 1.96 % | $ 2 B | ||
|
electroCore
ECOR
|
-9.7 M | $ 5.15 | 6.19 % | $ 28.4 K | ||
|
Haemonetics Corporation
HAE
|
623 M | $ 84.98 | 2.36 % | $ 4.28 B | ||
|
AngioDynamics
ANGO
|
-48.3 M | $ 10.02 | -8.29 % | $ 409 M | ||
|
Harvard Bioscience
HBIO
|
27.8 M | $ 0.66 | -1.92 % | $ 28 M | ||
|
The Cooper Companies
COO
|
2.38 B | $ 83.38 | -0.63 % | $ 16.6 B | ||
|
ICU Medical
ICUI
|
1.24 B | $ 152.88 | 1.7 % | $ 3.73 B | ||
|
Glaukos Corporation
GKOS
|
-21.6 M | $ 114.49 | 0.43 % | $ 5.55 B | ||
|
InfuSystem Holdings
INFU
|
33.3 M | $ 8.9 | -0.11 % | $ 184 M | ||
|
iRhythm Technologies
IRTC
|
-329 M | $ 188.16 | 0.41 % | $ 5.87 B | ||
|
Isoray
ISR
|
-58.9 M | - | 0.03 % | $ 108 M | ||
|
Repro Med Systems
KRMD
|
-10.8 M | $ 5.79 | 3.02 % | $ 264 M | ||
|
LeMaitre Vascular
LMAT
|
145 M | $ 85.05 | 1.55 % | $ 1.91 B | ||
|
Masimo Corporation
MASI
|
572 M | $ 138.18 | 0.8 % | $ 7.36 B | ||
|
Intuitive Surgical
ISRG
|
-1.88 B | $ 586.15 | -1.03 % | $ 208 B | ||
|
Merit Medical Systems
MMSI
|
363 M | $ 93.33 | 1.83 % | $ 5.43 B | ||
|
Microbot Medical
MBOT
|
-2.24 M | $ 2.19 | 3.55 % | $ 22.3 M | ||
|
Nephros
NEPH
|
-2.48 M | $ 5.07 | -1.74 % | $ 52.7 M | ||
|
Milestone Scientific
MLSS
|
-3.09 M | $ 0.29 | 2.24 % | $ 23.1 M | ||
|
Envista Holdings Corporation
NVST
|
244 M | $ 23.52 | 2.53 % | $ 4.05 B | ||
|
OraSure Technologies
OSUR
|
-266 M | $ 2.65 | 5.38 % | $ 197 M | ||
|
Pro-Dex
PDEX
|
15 M | $ 41.83 | 4.47 % | $ 138 M | ||
|
Predictive Oncology
POAI
|
1.4 M | $ 6.85 | 3.24 % | $ 37.4 M | ||
|
Pulse Biosciences
PLSE
|
-35.2 M | $ 14.71 | -3.26 % | $ 707 M | ||
|
Repligen Corporation
RGEN
|
-236 M | $ 165.12 | -2.32 % | $ 9.2 M | ||
|
ResMed
RMD
|
513 M | $ 250.85 | 1.07 % | $ 36.6 B | ||
|
BioLife Solutions
BLFS
|
-88.9 M | $ 24.91 | -1.97 % | $ 1.15 B | ||
|
STERIS plc
STE
|
1.78 B | $ 260.64 | 0.52 % | $ 25.7 B | ||
|
Stereotaxis
STXS
|
-14.3 M | $ 2.57 | -1.35 % | $ 207 M | ||
|
Retractable Technologies
RVP
|
-3 M | $ 0.76 | -0.53 % | $ 22.8 M | ||
|
STAAR Surgical Company
STAA
|
-105 M | $ 22.43 | 1.08 % | $ 1.1 B | ||
|
Utah Medical Products
UTMD
|
-60.6 M | $ 58.5 | 1.39 % | $ 212 M | ||
|
Teleflex Incorporated
TFX
|
1.37 B | $ 110.0 | -13.07 % | $ 5.15 B | ||
|
West Pharmaceutical Services
WST
|
-264 M | $ 274.0 | -1.62 % | $ 20 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.36 B | $ 12.53 | 1.25 % | $ 2.55 B |